



**ASX Release**

**27 October 2022**

### **Receipt of R&D Tax Incentive Rebate – Overseas Finding**

**Melbourne, Australia; Acrux Limited (ASX:ACR)** is pleased to announce receipt of \$362,197 from the Australian Tax Office in relation to a subsidiary company's Overseas Finding claim for the 2021/2022 financial year made within the Company's R&D Tax Incentive program.

A total of \$3,639,037 has now been received across the Company, with one smaller Overseas Finding claim still under assessment.

The R&D Tax Incentive is an Australian Government program which provides valued industry support to companies conducting eligible research and development.

Authorised for release by the Board of Acrux Limited.

**For more information, please contact:**

**Michael Kotsanis**

**Acrux Limited**

**CEO & Managing Director**

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

#### **About Acrux**

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Drawing on 25 years of experience and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)